First Trust Advisors
KERX

First Trust Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

First Trust Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-160,992
Closed -$749K – 2443
2017
Q4 		$749K Buy
+160,992
New +$887K ﹤0.01% 1953
2017
Q2 		– Sell
-83,220
Closed -$513K – 2507
2017
Q1 		$513K Sell
83,220
-80,961
-49% -$444K ﹤0.01% 2075
2016
Q4 		$962K Buy
+164,181
New +$897K ﹤0.01% 1840

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

First Trust Advisors's KERX Position: Q1 2018 in Review

First Trust Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 160,992 shares — an estimated $749K sold.

First Trust Advisors first reported a position in KERX in Q4 2016 and held it in 3 quarters. The position peaked at $962K in Q4 2016. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • First Trust Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • First Trust Advisors sold 160,992 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $749K.
  • First Trust Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q4 2016 and held it in 3 quarters.
  • First Trust Advisors's Keryx Biopharmaceuticals Inc position peaked at $962K in Q4 2016.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on First Trust Advisors's 13F filing for Q1 2018, filed 23 Apr 2018.